Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established therapies for type 2 diabetes and obesity, exerting beneficial effects on glycemic control and body weight. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.